Table 3.
Extracted data
| Participant characteristics | Total number |
| Gender | |
| Age | |
| Country | |
| Type of diabetic macular edema | |
| Diagnostic criteria | |
| Baseline visual acuity or changed in BCVA | |
| Visual fields | |
| Fluorescein angiography | |
| OCT-determined thickness of diabetic macular edema | |
| Patient inclusion and exclusion criteria | |
| Intervention | Agent |
| Dose | |
| Timing of first dose in relation to diagnosis | |
| Delivery route | |
| Frequency and treatment length | |
| Study and methodology | Study design |
| Trial identifiers | |
| Study size | |
| Randomization | |
| Masking, allocation concealment | |
| Duration of each study | |
| Primary outcomes | BCVA |
| Change in visual acuity | |
| OCT | |
| Secondary outcomes | Retinal thickness from baseline as measured by OCT5 |
| Anatomical measures: | |
| Presence of edema via direct fundoscopy | |
| Fluorescein angiography leakage | |
| Adverse effects: | |
| Ocular and systemic toxicity | |
| Ocular hypertension | |
| Anterior chamber reaction | |
| Lens opacity progression | |
| Endophthalmitis | |
| Blindness | |
| Additional data | Economic data, quality of life data |
| Treatment compliance and losses to follow-up | |
| Missing data | Authors contacted |
| Data has been entered in Review Manager 5 | |
| Fixed effect models used | |
| Data collection | Microsoft Excel® spreadsheet |
Abbreviations: BCVA, best-corrected visual acuity; OCT, optical coherence tomography.